Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Nanoliposomal irinotecan (nal-IRI) was originally developed using an efficient and high-loading capacity system to encapsulate irinotecan within a liposomal carrier, producing a therapeutic agent with improved biodistribution and pharmacokinetic characteristics compared to free drug. Specifically, administration of nal-IRI results in prolonged exposure of SN-38, the active metabolite of irinotecan, within tumors, while at the same time offering the advantage of less systemic toxicity than traditional irinotecan. These favorable properties of nal-IRI, confirmed in a variety of tumor xenograft models, led to its clinical evaluation in a number of disease indications for which camptothecins have proven activity, including in colorectal, gastric, and pancreatic cancers. The culmination of these clinical trials was the NAPOLI-1 (Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy) trial, an international Phase III study evaluating nal-IRI both alone and in combination with 5-fluorouracil and leucovorin in patients with metastatic pancreatic adenocarcinoma following progression on gemcitabine-based chemotherapy. Positive results from NAPOLI-1 led to approval of nal-IRI (with 5-fluorouracil/leucovorin) in October 2015 by the US Food and Drug Administration specifically for the treatment of metastatic pancreatic cancer in the second-line setting and beyond, a clinical context in which there had previously been no accepted standard of care. As such, nal-IRI represents an important landmark in cancer drug development, and potentially ushers in a new era where a greater number of patients with advanced pancreatic cancer can be sequenced through multiple lines of therapy translating into meaningful improvements in survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Le, D. T., Wang-Gillam, A., Picozzi, V., Greten, T. F., Crocenzi, T., Springett, G., Morse, M., Zeh, H., Cohen, D., Fine, R. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4244 · Cited by 611
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
Chang, T. C., Shiah, H. S., Yang, C. H., Yeh, K. H., Cheng, A. L., Shen, B. N., Wang, Y. W., Yeh, C. G., Chiang, N. J., Chang, J. Y., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2671-x · Cited by 100
Cited by
Wang-Gillam, A., Hubner, R. A., Siveke, J. T., Von Hoff, D. D., Belanger, B., de Jong, F. A., Mirakhur, B., & Chen, L.-T. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.007 · Cited by 342
The long story of camptothecin: From traditional medicine to drugs
Martino, E., Della Volpe, S., Terribile, E., Benetti, E., Sakaj, M., Centamore, A., Sala, A., & Collina, S. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.12.085 · Cited by 296
Potential applications and human biosafety of nanomaterials used in nanomedicine
Su, H., Wang, Y., Gu, Y., Bowman, L., Zhao, J., & Ding, M. (2018) · Journal of Applied Toxicology · doi:10.1002/jat.3476 · Cited by 178
Axial pharmaceutical properties of liposome in cancer therapy: Recent advances and perspectives
Kiaie, S. H., Mojarad-Jabali, S., Khaleseh, F., Allahyari, S., Taheri, E., Zakeri-Milani, P., & Valizadeh, H. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119269 · Cited by 87
Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer
Lei, F., Xi, X., Batra, S. K., & Bronich, T. K. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.255786 · Cited by 51
Metadata
- Authors
- Ko, A.
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2016-03
- Volume
- 11
- Pages
- 1225
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W2314883044
- Cited by
- 42
- References
- 2
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.